Prostate Cancer Foundation (PCF): Movember – PCF Challenge Award in immunotherapy for the treatment of advanced, metastatic prostate cancer

This Award will support one large-scale research project concerning metastatic prostate cancer over a duration of 2 years, providing up to $1 million for one team. The Award will focus on funding translational and clinical science to advance immunotherapy. Areas of particular interest include but are not limited to: (1) adoptive engineered T cell therapy; (2) Checkpoint inhibition therapy; (3) Development of rational combination/sensitization immunotherapy regimens; (4) Characterization of biomarker(s) that predict response or innate resistance to immunotherapy; (5) Other novel first-in-field immunotherapy strategies with near term translational potential. Proposals must be from teams of at least 3 highly experienced investigators capable of providing unique scientific expertise to the solution of a significant problem in prostate cancer research. The team may be assembled from one institution or several institutions from across the globe, and must embed a young investigator as an integral contributor to the team.
http://www.pcf.org/site/c.leJRIROrEpH/b.5849007/k.F70A/Open_RFAs.htm